A comprehensive review of immune checkpoint inhibitors for cancer treatment
The DOI matches its Crossref record; 612 of the 626 references it cites were found in a registry or an index.
Abstract
Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint proteins like PD-1/PD-L1 and CTLA-4 was pivotal in developing cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have shown great success, with FDA-approved drugs like PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab, Tremelimumab), alongside LAG-3 inhibitor Relatlimab. Research continues on new checkpoints like TIM-3, VISTA, B7-H3, BTLA, and TIGIT. Biomarkers like PDL-1 expression, tumor mutation burden, interferon-γ presence, microbiome composition, and extracellular matrix characteristics play a crucial role in predicting responses to immunotherapy with checkpoint inhibitors. Despite their effectiveness, not all patients experience the same level of benefit, and organ-specific immune-related adverse events (irAEs) such as rash or itching, colitis, diarrhea, hyperthyroidism, and hypothyroidism may occur. Given the rapid advancements in this field and the variability in patient outcomes, there is an urgent need for a comprehensive review that consolidates the latest findings on immune checkpoint inhibitors, covering their clinical status, biomarkers, resistance mechanisms, strategies to overcome resistance, and associated adverse effects. This review aims to fill this gap by providing an analysis of the current clinical status of ICIs, emerging biomarkers, mechanisms of resistance, strategies to enhance therapeutic efficacy, and assessment of adverse effects. This review is crucial to furthering our understanding of ICIs and optimizing their application in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Cited by
Items 201–252 of 252
Cancer Signaling Pathways and Cancer Biology
Nair, A., Prasad, A. P., Anand, A. V., Shyl, D., & Yesupatham, S. K. (2026) · Studies in Rhythm Engineering · doi:10.1007/978-981-95-8938-8_7
Cancer treatment: A review of methods, drug combinations, availability, and ethical considerations
Novruzov, M., Mammadova, M., Khan, W. U., & Shiraliyeva, U. (2026) · Microbes & Immunity · doi:10.36922/mi025450119
Immune checkpoint inhibitor (ICI) associated corneal allograft rejection
Marjon, P. P., Echegoyen, J. C., Schanzlin, D. J., Gibbs, P. G., & McClay, E. F. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101306
Yang, Z., Huang, Y., Li, H., Ms, C., Zeng, T., Zhang, S., Chen, C., & Zheng, B. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.112038
Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy
Ge, X., Han, D., Wang, J., Dai, X., Ma, C., & Chen, F. (2026) · MedComm · doi:10.1002/mco2.70882
Jastrzębska, A., Bukowska, M., & Zagórska, A. (2026) · Oncoreview · doi:10.24292/01.or.153202226
Li, F., Wang, Y., Xu, Z., Zhu, M., Su, K., Yang, X., & Wu, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1862775
Zhang, N., Zhou, Y., Li, H., & Liu, H. (2026) · Immunologic Research · doi:10.1007/s12026-026-09819-6
Menaquinone-4 protects CD8+ T cells from ferroptosis to enhance anti-tumor immunity
Wang, J., Wang, W., Fan, S., Liang, L., Hu, H., Song, Z., Zhang, Y., Zhang, J., Xiao, W., Zhang, B., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3349-0
Unconventional guardians of the brain: MAIT cells as emerging players in glioblastoma immunity
Eddy, E. M., Patton, T., Barrow, A. D., & Corbett, A. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1896626
Haghi, T., Yazdani, A., Ebrahimi, S. A., Memarzadeh, M., Yazdani, H., Asadirad, A., & Maleki, L. A. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04436-7
Gao, M., Liu, X., Wu, L., Jiang, Y., Yu, J., & Zhang, Y. (2026) · Molecular and Cellular Biology · doi:10.1080/10985549.2026.2717162
Alhassan, L., Alrabadi, B., Batarseh, S. F., Alghzawi, Y., Bandak, N., Badwan, A., & Alkayed, H. A. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2717074
Karataş, R. B., Alras, Y., Tekiner, S., Zıkşahna, K., Merdan, S., & Ihlamur, M. (2026) · Immunologic Research · doi:10.1007/s12026-026-09824-9
Hu, Y., Maher, H., Du, L., & Chen, X. (2026) · Translational Cancer Research · doi:10.21037/tcr-2026-1404
Chen, H., Shan, Y., Xu, H., Xuan, K., Ren, T., & Zhao, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1919841
Hu, Y., Teng, C., & Zhang, D. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1876450
Attenuated Salmonella-Mediated Delivery of GSDMD Potentiates PD-1 Blockade Therapy against MelanomaPreprint
Jia, X., Yuan, Y., Huang, Y., Li, K., Xu, X., Zhang, X., Zhang, Y., Zhao, T., Wang, L., & Jia, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.02.748795
Zubac, D., Niels, T., Kranjc, D., & Baumann, F. T. (2026) · Physiological Reports · doi:10.14814/phy2.71090
A Multisource-Integrated Atlas of Adverse Reactions Associated with Immunological Agents
Yin, J., Qi, Y., Bao, Y., Hong, D., Qiu, D., Zeng, S., Li, F., & Zhao, Q. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101785
Mureșan, X. M., Țigu, A. B., Roman, A., & Romani, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1965471
Lin, X., Zhang, J., Fan, Z., Yang, J., Yi, S., Wang, H., Zou, H., Hu, L., Zhu, W., Lin, Y., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014273
Lazcano-Ornelas, A., & Tillu, N. (2026) · Lymphatics · doi:10.3390/lymphatics4030046
Tan, Y., & Song, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1902939
Gray, O. (2025) · Otago University Research Archive (University of Otago)
Molecular Architecture and Clinical Landscape of Immune Checkpoint Receptors and Ligands
Czosnek, M., Sowa, A., Rolek, Ł., Grywalska, E., Mertowski, S., & Mertowska, P. (2026) · Antibodies · doi:10.3390/antib15050084
Perspective Chapter: Microbiome Predictive Value for Immunotherapy Response
Gales, L. N., Ghencea, I. A., Serban, E. C., & Trifanescu, O. G. (2026) · Pharmaceutical science. · doi:10.5772/intechopen.1017715
Hypothyroidism in patients treated with immune checkpoint inhibitors
Laghmouch, N., Meeusen, I., & Twickler, T. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30261-9.00022-x
Recent advances and future challenges of bispecific antibodies in lung cancer
Du, M., Han, Y., Jin, R., & Li, H. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105604
Guiding the Application of Immunotherapy in Nonsmall Cell Lung Cancer: The Role of Biomarkers
Sun, Y., Chu, X., Wang, X., Li, W., Zhu, X., Zhu, G., Ma, X., He, X., & Li, J. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70342
Gut microbiome in immuno-oncology: potential for clinical exploitation
Margarita, E., Saito, K., Bisegna, P., Ferrari, M., Valeriani, E., Guerrieri, M., Funaro, B., Feliciani, D., Gasbarrini, A., Porcari, S., et al. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102143
Checkpoint Inhibitor–Induced Orbital Myositis Mimicking Extraocular Muscle Metastasis
Dezard, V. A., Aramrat, C., Alshafai, L., & Margolin, E. (2026) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002517
Naeem, R. K., Abdulamir, A. S., & Alosami, M. H. (2026) · Journal of the Faculty of Medicine Baghdad · doi:10.32007/jfacmedbaghdad3368
The application of PD-1 and its ligands in immune gene therapy
Käyhty, P. (2026) · UEF eRepo (University of Eastern Finland)
Solovăstru, L., Nechifor-Boila, A. I., Borda, A., Loghin, A., & Nechifor-Boilă, A. C. (2026) · Acta Marisiensis. Seria Medica · doi:10.62838/amsm-2026-0020
Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy
张佳宇, Xing, S., Zhang, S., Hao, Y., Qu, X., Bao, W., Hao, M., Sun, H., Dong, M., Zhang, H., et al. (2026) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70079
He, X.-Y., Du, K., Yue, C., Li, C., Zhu, Y., Tang, Y., Wang, H., Yang, M., He, F., & Jiang, X. (2026) · Biomarker Research · doi:10.1186/s40364-026-01014-x
Ebanoidze, L., Koval, A. A., Pigarova, E. A., Dzeranova, L. K., Starostina, E. A., Орлова, К. В., Nikankina, L. V., Kolesnikova, G. S., & Platonova, N. M. (2026) · Clinical and experimental thyroidology · doi:10.14341/ket12852
Foundations of Cancer and Parenteral Oncology Therapies
Moreira, F. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch001
CD274 Knockout Promotes Bone Formation and Reduces Osteoclast Activity
Assaad, H. E., Komrakova, M., Lienenklaus, S., Decker, S., Neunaber, C., & Bundkirchen, K. (2026) · Calcified Tissue International · doi:10.1007/s00223-026-01627-2
Nanoengineered STING agonists for cancer therapy: toward immunodynamic control
Liu, N., Wang, X., Zhang, W., Kan, Y., Petrovna, B. M., Wang, Z., Kong, X., & Wang, J. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01860-0
Hu, J. (2026) · Theoretical and Natural Science · doi:10.54254/2753-8818/2027.mb38003
Model Systems for the Study of Malignant Melanoma
Reed, S., & Gregg, R. K. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5619-8_1
Yegodayev, K. M., Perelman, G., Shami, T., Kaufman, B., Raviv, D., Marripati, D., Khateeb, A., Ben-Uri, R., Galibov-Levi, O., Milo, I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.26.761755
Zhang, Y., Duan, H., Xu, G., & Yang, J. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13110550
Vieira-Costa, M. C., Júnior, L. T., & Sogayar, M. C. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.10.016
Kang, M., Kim, Y., & Park, J.-S. (2026) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2026.0030
Teschke, R., & Danan, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1974945
Samidurai, A., Saravanan, P. B., Chintkuntlawar, P., Kottury, N., Gupta, G., Xi, L., & Kukreja, R. C. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168531
Mi, L., Tang, C., & Zhang, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1977329
Cancer and Cardiovascular Diseases: Common Mechanisms and Strategies of Prevention
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-9013-3
mRNA‑Encoded Antibodies as a Powerful Arsenal Against Superbugs‐Induced Sepsis
Pei, S., Guo, Z., Cheng, L., Mingxing, L., Guan, S., Xu, L., Liao, R., Xiao, Q., Wu, W., & Zeng, H. (2026) · Drug Development Research · doi:10.1002/ddr.70412
Metadata
- Authors
- Arafat Hossain, M.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 143
- Issue
- Pt 2
- Pages
- 113365
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W4403679157
- Cited by
- 178
- References
- 626
- FWCI
- 27.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.